VPT:CC - Ventripoint to Exhibit at the American College of Cardiology 71st Annual Scientific Session and Expo and Correction to North Equities Corp Grant of Stock Options
(TheNewswire)
Toronto, Ontario – TheNewswire– April 1, 2022 - Ventripoint Diagnostics Ltd . (" Ventripoint " or the " Company "),(TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce thatit will be exhibiting at the 71st Annual Scientific Session and Expo,hosted by the American College of Cardiology (ACC) between April 2-4,2022, in Washington, D.C, United States.
The ACC is a not-for-profit medical community that hasover 54,000 medical professionals worldwide. The ACC aims to providethe best care possible for patients with cardiovascular disease and tohelp raise awareness about the prevention of cardiovascular disease.
The conference will be highlighting the latestadvancements in cardiac care and will be holding specific educationsessions for practitioner continuing education. Some of the keynotetopics will include health equity in cardiovascular diseaseprevention, technology, heart healthy diet, and more. The conferencealready has over 18,000 members attending and will provide anexcellent opportunity for Ventripoint to connect with thecardiovascular community and engage in pressing topics within thefield.
Additionally, Ventripoint would like to correct thepress release dated March 2, 2022, regarding options for marketingfirm North Equities Corp. The Company has granted an aggregate of660,000 stock options with an exercise price of $0.33 per shareexercisable for a period of two years vesting quarterly in accordancewith TSXV policies.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.